APC-based Therapy Development Service

Antigen-presenting cell-based therapy (APC-based therapy) is a type of immunotherapy that uses antigen-presenting cells (APCs) to activate and enhance the body's immune response to recognize and attack cancer cells. At Alfa Cytology, we are dedicated to offering comprehensive, end-to-end services for APCs-based therapy development, specifically targeting prostate cancer.

Introduction to APC-based Therapy

Antigen-presenting cells (APCs) are a class of immune cells that are capable of ingesting and processing antigens and presenting the processed antigens to T cells. Antigen-presenting cell (APCs)-based therapy is an innovative prostate cancer treatment strategy that recognizes and attacks cancer cells through an enhanced immune cell response.

Classification of APCs

APCs are a specialized class of immune cells whose primary role is to recognize, ingest, process, and present antigens, thereby activating T cells and triggering an immune response. And APCs can be categorized into specialized APCs and nonspecialized APCs. Specialized APCs, which have a potent antigen-presenting capacity, include dendritic cells (DCs), macrophages, and B cells.

	Dendritic Cells Dendritic cells (DCs) are the most functional and specialized APCs, which are able to efficiently uptake, process and deliver antigens. Depending on their origin, DCs can be categorized into two main groups, including myeloid DCs (MDC) and lymphoid DCs (DC).
	Macrophages Macrophages are differentiated from monocytes and are widely distributed in a variety of tissues, performing the functions of phagocytosis and digestion of pathogens. After digesting a pathogen, macrophages present the pathogen's antigen to the appropriate helper T (Th) cells, which present the antigenic peptide to T cells via MHC molecules.
	B Lymphocytes B cells are a key component of the adaptive immune system, and they produce and secrete antibodies that recognize and neutralize foreign antigens. In some cases, B cells also act as APCs, activating T cells by taking up antigens via B cell receptors (BCRs) on their surface and presenting antigenic peptides to CD4+ T cells via MHC class II molecules.

Advantages of APCs-based Therapy

APCs- based Therapy offer several advantages in prostate cancer therapy, as described below.

Specificity

APCs recognize and present tumor-specific antigens, which are molecules that are specific to cancer cells or are expressed at high levels in cancer cells. In this way, APCs activate specific immune responses against cancer while reducing damage to normal cells.

Persistence

Activated APCs stimulate the production of memory T cells, which persist in the body and provide long-term immune protection. This means that once the immune system is activated, it is able to "remember" the characteristics of the tumor and respond quickly when the tumor reappears.

Adaptation

APCs can target multiple types of cancer because they are based on presented antigens rather than being specific to a single cancer type. This adaptability allows APCs to respond to tumor heterogeneity and variability and provide treatment for patients with different types of cancer.

Our Services

One-stop Solutions of APCs-based Therapy Development

Today, APCs-based therapy has emerged as a pivotal area of exploration within the realm of prostate cancer therapy. Our mission is to advance prostate cancer therapy development by providing clients with efficient, innovative, and reliable solutions. If you are interested in our services, please don't hesitate to contact us for further information and pricing details.